当前位置: 首页 >> 检索结果
261. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study.
作者: Su Jin Chung.;Donghee Kim.;Ji Hyun Song.;Hae Yeon Kang.;Goh Eun Chung.;Jeongmin Choi.;Young Sun Kim.;Min Jung Park.;Joo Sung Kim.
来源: Gut. 2014年63卷5期785-91页
Virtual chromoendoscopy (CE) is expected to enhance adenoma yield and reduce variation in performance between colonoscopists. This study aimed to compare the efficacy of narrow band imaging (NBI), flexible spectral imaging CE (FICE) and white light (WL) colonoscopy and their impact for less experienced endoscopists.
262. Endoscopic versus histological characterisation of polyps during screening colonoscopy.
作者: Guido Schachschal.;Michael Mayr.;Andras Treszl.;Klaus Balzer.;Karl Wegscheider.;Jens Aschenbeck.;Alireza Aminalai.;Rolf Drossel.;Andreas Schröder.;Mathias Scheel.;Carl-Hermann Bothe.;Jens-Peter Bruhn.;Wolfgang Burmeister.;Gabriela Stange.;Christina Bähr.;Ralf Kießlich.;Thomas Rösch.
来源: Gut. 2014年63卷3期458-65页
As screening colonoscopy becomes more widespread, the costs for histopathological assessment of resected polyps are rising correspondingly. Reference centres have published highly accurate results for endoscopic polyp classification. Therefore, it has been proposed that, for smaller polyps, the differential diagnosis that guides follow-up recommendations could be based on endoscopy alone.
263. Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants.
作者: Jihane Romanos.;Anna Rosén.;Vinod Kumar.;Gosia Trynka.;Lude Franke.;Agata Szperl.;Javier Gutierrez-Achury.;Cleo C van Diemen.;Roan Kanninga.;Soesma A Jankipersadsing.;Andrea Steck.;Georges Eisenbarth.;David A van Heel.;Bozena Cukrowska.;Valentina Bruno.;Maria Cristina Mazzilli.;Concepcion Núñez.;Jose Ramon Bilbao.;M Luisa Mearin.;Donatella Barisani.;Marian Rewers.;Jill M Norris.;Anneli Ivarsson.;H Marieke Boezen.;Edwin Liu.;Cisca Wijmenga.; .
来源: Gut. 2014年63卷3期415-22页
The majority of coeliac disease (CD) patients are not being properly diagnosed and therefore remain untreated, leading to a greater risk of developing CD-associated complications. The major genetic risk heterodimer, HLA-DQ2 and DQ8, is already used clinically to help exclude disease. However, approximately 40% of the population carry these alleles and the majority never develop CD.
264. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
作者: Adrian G McNicholl.;Alicia C Marin.;Javier Molina-Infante.;Manuel Castro.;Jesús Barrio.;Julio Ducons.;Xavier Calvet.;Cristobal de la Coba.;Miguel Montoro.;Felipe Bory.;Angeles Perez-Aisa.;Montserrat Forné.;Javier P Gisbert.; .
来源: Gut. 2014年63卷2期244-9页
No trial has compared non-bismuth quadruple 'sequential' and 'concomitant' regimens in settings with increasing clarithromycin rates. The study aims to compare the effectiveness and safety of these therapies for Helicobacter pylori treatment.
265. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
作者: Pieter Dewint.;Bettina E Hansen.;Elke Verhey.;Bas Oldenburg.;Daniel W Hommes.;Marieke Pierik.;Cyriel I J Ponsioen.;Hendrik M van Dullemen.;Maurice Russel.;Ad A van Bodegraven.;C Janneke van der Woude.
来源: Gut. 2014年63卷2期292-9页
To assess whether a combination of adalimumab and ciprofloxacin is superior to adalimumab alone in the treatment of perianal fistulising Crohn's disease (CD).
266. Telephone-based re-education on the day before colonoscopy improves the quality of bowel preparation and the polyp detection rate: a prospective, colonoscopist-blinded, randomised, controlled study.
作者: Xiaodong Liu.;Hui Luo.;Lin Zhang.;Felix W Leung.;Zhiguo Liu.;Xiangping Wang.;Rui Huang.;Na Hui.;Kaichun Wu.;Daiming Fan.;Yanglin Pan.;Xuegang Guo.
来源: Gut. 2014年63卷1期125-30页
Despite advances in bowel preparation methods, the quality of bowel preparation in some patients undergoing colonoscopy remains unsatisfactory. The effect of telephone re-education (TRE) on the day before colonoscopy on the quality of bowel preparation and other outcome measures had not been studied.
267. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
作者: Lloyd Mayer.;William J Sandborn.;Yuriy Stepanov.;Karel Geboes.;Robert Hardi.;Michael Yellin.;Xiaolu Tao.;Li An Xu.;Luisa Salter-Cid.;Sheila Gujrathi.;Richard Aranda.;Allison Y Luo.
来源: Gut. 2014年63卷3期442-50页
Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC.
268. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
作者: Simon P L Travis.;Silvio Danese.;Limas Kupcinskas.;Olga Alexeeva.;Geert D'Haens.;Peter R Gibson.;Luigi Moro.;Richard Jones.;E David Ballard.;Johan Masure.;Matteo Rossini.;William J Sandborn.
来源: Gut. 2014年63卷3期433-41页
Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ulcerative colitis (UC).
269. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
作者: Bindia Jharap.;Nanne K H de Boer.;Pieter Stokkers.;Daniel W Hommes.;Bas Oldenburg.;Gerard Dijkstra.;C Janneke van der Woude.;Dirk J de Jong.;Chris J J Mulder.;Ruurd M van Elburg.;Adriaan A van Bodegraven.; .
来源: Gut. 2014年63卷3期451-7页
Several studies have demonstrated a favourable safety profile for thiopurine use for inflammatory bowel disease (IBD) during pregnancy. We performed a study in pregnant patients with IBD who were using thiopurines, in order to determine the influence of pregnancy on thiopurine metabolism and to assess intrauterine exposure of the fetus to thiopurines.
270. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
作者: Yaron Rotman.;Mazen Noureddin.;Jordan J Feld.;Jeremie Guedj.;Michael Witthaus.;Hwalih Han.;Yoon J Park.;Su-Hyung Park.;Theo Heller.;Marc G Ghany.;Edward Doo.;Christopher Koh.;Adil Abdalla.;Naveen Gara.;Souvik Sarkar.;Emmanuel Thomas.;Golo Ahlenstiel.;Birgit Edlich.;Rachel Titerence.;Leah Hogdal.;Barbara Rehermann.;Harel Dahari.;Alan S Perelson.;Jay H Hoofnagle.;T Jake Liang.
来源: Gut. 2014年63卷1期161-9页
Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C.
271. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
作者: Thomas Reiberger.;Gregor Ulbrich.;Arnulf Ferlitsch.;Berit Anna Payer.;Philipp Schwabl.;Matthias Pinter.;Birgit B Heinisch.;Michael Trauner.;Ludwig Kramer.;Markus Peck-Radosavljevic.; .
来源: Gut. 2013年62卷11期1634-41页
Non-selective β-blockers or endoscopic band ligation (EBL) are recommended for primary prophylaxis of variceal bleeding in patients with oesophageal varices. Additional α-adrenergic blockade (as by carvedilol) may increase the number of patients with haemodynamic response (reduction in hepatic venous pressure gradient (HVPG) of ≥ 20% or to values <12 mm Hg).
272. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women.
作者: Evelyne M Dewulf.;Patrice D Cani.;Sandrine P Claus.;Susana Fuentes.;Philippe G B Puylaert.;Audrey M Neyrinck.;Laure B Bindels.;Willem M de Vos.;Glenn R Gibson.;Jean-Paul Thissen.;Nathalie M Delzenne.
来源: Gut. 2013年62卷8期1112-21页
To highlight the contribution of the gut microbiota to the modulation of host metabolism by dietary inulin-type fructans (ITF prebiotics) in obese women.
273. Surface maturation scoring for oesophageal squamous intraepithelial neoplasia: a novel diagnostic approach inspired by first endomicroscopic 3-dimensional reconstruction.
作者: Ming Li.;Xiu-Li Zuo.;Tao Yu.;Xiao-Meng Gu.;Cheng-Jun Zhou.;Zhen Li.;Hong Liu.;Rui Ji.;Yan-Yan Dong.;Chang-Qing Li.;Yan-Qing Li.
来源: Gut. 2013年62卷11期1547-55页
Loss of surface maturation and cytonuclear atypia have been regarded as the pathological 'gold standard' for the diagnosis of oesophageal squamous cell intraepithelial neoplasia. However, there has been no satisfactory endomicroscopic method similar to this pathological approach to detect surface maturation and screen for oesophageal squamous cell intraepithelial neoplasia. The aim of this study was to apply a 3-dimensional (3D) confocal endomicroscopic imaging technique to investigate the surface maturation of the oesophageal epithelium and develop new 2-dimensional confocal endomicroscopic criteria based on surface maturation.
274. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
作者: Pietro Lampertico.;Mauro Viganò.;Giovan Giuseppe Di Costanzo.;Evangelista Sagnelli.;Massimo Fasano.;Vito Di Marco.;Sara Boninsegna.;Patrizia Farci.;Silvia Fargion.;Tiziana Giuberti.;Claudio Iannacone.;Loredana Regep.;Benedetta Massetto.;Floriana Facchetti.;Massimo Colombo.; .
来源: Gut. 2013年62卷2期290-8页
Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.
275. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus.
作者: Alba Rocco.;Debora Compare.;Pietro Coccoli.;Ciro Esposito.;Antimo Di Spirito.;Antonio Barbato.;Pasquale Strazzullo.;Gerardo Nardone.
来源: Gut. 2013年62卷5期766-73页
In vitro, vitamin B12 acts as a natural inhibitor of hepatitis C virus (HCV) replication.
276. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
作者: Volker Heinemann.;Ursula Vehling-Kaiser.;Dirk Waldschmidt.;Erika Kettner.;Angela Märten.;Cornelia Winkelmann.;Stefan Klein.;Georgi Kojouharoff.;Thomas C Gauler.;Ludwig Fischer von Weikersthal.;Michael R Clemens.;Michael Geissler.;Tim F Greten.;Susanna Hegewisch-Becker.;Oleg Rubanov.;Gerold Baake.;Thomas Höhler.;Yon D Ko.;Andreas Jung.;Sascha Neugebauer.;Stefan Boeck.
来源: Gut. 2013年62卷5期751-9页
AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was compared with a reverse experimental sequence of capecitabine/erlotinib followed by gemcitabine.
277. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
作者: Bruce E Sands.;Seymour Katz.;Douglas C Wolf.;Brian G Feagan.;Tao Wang.;Lisa-Marie Gustofson.;Cindy Wong.;Margaret K Vandervoort.;Stephen Hanauer.
来源: Gut. 2013年62卷9期1288-94页
Activated granulocytes and monocytes may contribute to the pathogenesis of Crohn's disease (CD). In small, uncontrolled studies, granulocyte/monocyte apheresis (GMA) has shown promise in treating CD. We conducted a randomised, double-blind study to compare GMA with a sham procedure in patients with moderate to severe CD.
278. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
作者: Nicholas J Shaheen.;Hans Denison.;Karin Björck.;Maria Karlsson.;Debra G Silberg.
来源: Gut. 2013年62卷9期1248-55页
Lesogaberan (AZD3355) is a novel γ-aminobutyric acid B-type receptor agonist designed to treat gastro-oesophageal reflux disease (GERD) by inhibiting transient lower oesophageal sphincter relaxations. A randomised, double-blind, placebo-controlled, multi-centre phase IIb study was performed to assess the efficacy and safety of lesogaberan as an add-on to proton pump inhibitor (PPI) therapy in patients with GERD who are partially responsive to PPI therapy (ClinicalTrials.gov reference: NCT01005251).
279. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
作者: Paul J Rutgeerts.;Richard N Fedorak.;Daan W Hommes.;Andreas Sturm.;Daniel C Baumgart.;Brian Bressler.;Stefan Schreiber.;John C Mansfield.;Marna Williams.;Meina Tang.;Jennifer Visich.;Xiaohui Wei.;Mary Keir.;Diana Luca.;Dimitri Danilenko.;Jackson Egen.;Sharon O'Byrne.
来源: Gut. 2013年62卷8期1122-30页
Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety and pharmacology of etrolizumab in patients with moderate to severe UC.
280. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation.
作者: Adil E Bharucha.;Phillip Low.;Michael Camilleri.;Erica Veil.;Duane Burton.;Yogish Kudva.;Pankaj Shah.;Tonette Gehrking.;Alan R Zinsmeister.
来源: Gut. 2013年62卷5期708-15页
Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and is managed with laxatives. Cholinesterase inhibitors increase colonic motility. This study evaluated the effects of a cholinesterase inhibitor on gastrointestinal and colonic transit and bowel function in diabetic patients with constipation.
|